CD274 and non-small cell lung carcinoma: In the IMpower110 trial (NCT02409342), atezolizumab monotherapy demonstrated superior overall survival (OS) compared to chemotherapy in PD-L1-positive NSCLC patients with high expression (TC ≥50% or IC ≥10%), with a median OS of 20.2 months versus 13.1 months, supporting its role as a first-line option for selected patients.